Bringing prescription-free medicines and pharmacy products to customers in Berlin, Hamburg, Munich, Frankfurt am Main, and now Cologne and Düsseldorf in under 30 minutes (between 8 am and midnight), Berlin-based MAYD has raised €30 million in a Series A funding round.
The lion's share of the new funding will be used to continue expansion plans, starting by further supporting recently launched services in Cologne and Düsseldorf. The prescription-free drug runner has raised €43 million since October of last year.
A telepharmacy platform at heart, MAYD offers customers access to more than 2,000 prescription-free medicines and other pharmacy products without the need to leave their doorstep via an app, a Godsend when you’re feeling under the weather. And yes, MAYD also has a selection of hangover cures on the menu. Do these folks know their audience, or what? Ah, Berlin.
As an added benefit these same customers can use the service to seek advice from pharmacists by phone.
However, MAYD isn’t subcontracting its network of delivery riders out to a third party, and in doing so, is also operating in the field of logistics, and naturally q-commerce. Which, leaders this author to ponder if MAYD is doing anything with the data it’s surely gathering, and what else we might see from the company in the future.
"Until the introduction of the e-prescription, we will continuously develop the service for our customers and would like to further expand our leading position in the market,” commented MAYD co-founder Lukas Pieczonka. “The financing round gives us a great opportunity to convince even more customers of MAYD's service, initially through the promotion of the model across different cities in Germany.”
MAYD’s €30 million Series A funding round was led by new investor Lightspeed Venture Partners, with previous investors Target Global, 468 Capital, and Earlybird all following on.
"The MAYD team convinced us early on with its concept and proved in Germany that the demand for a digital delivery platform around pharmacy products is tremendous. The US market has shown us by various examples that the potential goes far beyond the mere sale of pharmacy products, and we think the opportunity across Germany and the rest of Europe is even bigger,” commented Lightspeed’s Paul Murphy. “Last but not least, the team around the two founders Lukas and Hanno inspired us.”
Would you like to write the first comment?
Login to post comments